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Introduction: Neural stem cells (NSCs) are among the most promising candidates for cell replacement therapy in
neuronal injury and neurodegenerative diseases. One of the remaining obstacles for NSC therapy is to overcome
the alloimmune response on NSCs by the host.
Methods: To investigate the mechanisms of immune modulatory function derived from the interaction of human
NSCs with allogeneic T cells, we examined the immune regulatory effects of human NSCs on allogeneic T cells
in vitro.
Results: Significantly, NSCs induced apoptosis of allogeneic T cells, in particular CD4+ T cells. Interaction of CD70
on NSCs and CD27 on CD4+ T cells mediated apoptosis of T cells. Thus, blocking CD70–CD27 interaction prevented
NSC-mediated death of CD4+ T cells.
Conclusions: We present a rational explanation of NSC-induced immune escape in two consecutive stages. First,
CD70 constitutively expressed on NSCs engaged CD27 on CD4+ T cells, which induced Fas ligand expression on
CD4+ T cells. Second, CD4+ T-cell apoptosis was followed by Fas–Fas ligand interaction in the CD4+ T cells.
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Neural stem cells (NSCs) are among the most promising
candidates for cell replacement therapy in neuronal in-
jury and neurodegenerative diseases. Derivation methods
to produce neuronal cells with specific functions from
NSCs, such as dopaminergic neurons, have also been
established [1]. Therefore, it is highly likely that NSCs
will become the first choice for stem cell treatment.
Most cellular and organ transplantation between two un-
related individuals results in graft rejection. However, it has
been often found that stem cell transplantation could es-
cape the graft rejection [2-4], presumably by inducing apop-
tosis of T cells via Fas–Fas ligand (FasL) interaction [5].* Correspondence: curie@snu.ac.kr
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reproduction in any medium, provided the orTransplantation of rodent embryonic stem cells (ESCs)
into allogeneic recipients indicated that they may have
immune-privileged properties. The injection of undiffer-
entiated rat ESC-like cells into fully MHC-mismatched
rats led to the induction of donor-specific immuno-
logical tolerance [6]. Moreover, undifferentiated allogen-
eic murine ESCs led to engraftment of these cells in the
thymus, spleen and liver, with establishment of mixed
hematopoietic chimerism [7]. This also proved that ESCs
represent a good research tool for possible therapeutic
applications in solid organ transplantation because of
their capability, when given alone, to induce tolerance to
semi-allogeneic solid organ allograft [8].
NSC transplantation could be applied to the brain
because this organ is subject to less surveillance by the
immune system than other parts of the body, and like brain
cells NSCs may display characteristics of cells with immune
privilege. Consistent with this idea, T cells that infiltrate
around transplanted NSCs in a stroke model exhibited little. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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potential to protect cells of the central nervous system
against harmful T-cell infiltration [10]. In a related study,
the systemic injection of neuronal stem/precursor cells pro-
vided a remarkable amelioration of the pathological features
of experimentally induced autoimmune encephalomyelitis
and other preclinical models of neurological disorders
[11,12].
In this paper, we have investigated the mechanisms re-
sponsible for NSC-induced immune tolerance. Our studies
indicate a two-stage model whereby human NSCs induce
apoptosis of allogeneic CD4+ T cells. First, CD70 expressed
constitutively on NSCs engage CD27 on CD4+ T cells and
induce upregulation of FasL expression on the CD4+
T cells. Second, T cells thereafter undergo apoptosis from
fratricide; that is, through Fas–FasL interaction in the
CD4+ T cells themselves.
Materials and methods
Cell culture
The immortalized human embryonic neural stem cell line,
HB1.F3 was generated in a previous study by transfection
of primary cells from fetal human telencephalon tissue
of 14 weeks gestation with amphotropic, replication-
incompetent retroviral vector containing v-myc [13].
Primary NSCs were provided by Professor Kim (Korea
University, Seoul, Korea) [14,15]. HB1.F3 cells and primary
NSCs were cultured in DMEM with 10% heat-inactivated
fetal bovine serum (Gibco, Carlsbad, CA, USA), and 1%
antibiotic–antimycotic solution (Gibco, Carlsbad, CA,
USA). Human umbilical cord blood mesenchymal stem
cells purchased from MEDIPOST Co., Ltd (Seoul, Korea)
were used. Human umbilical cord blood-derived mesen-
chymal stem cells were isolated and expanded as
described previously [16,17]. Cultures were maintained
in a humidified incubator at 37°C containing 5% CO2.
CD4+ and CD8+ T-cell preparation
Whole blood was collected from healthy volunteer donors
(n = 55, age: 24.85 ± 3.52, sex: male/female = 36/19). The
institutional review board of the Seoul National University
Hospital approved this study, and all volunteers provided
written informed consent. Peripheral blood mononuclear
cells were isolated by Ficoll-Paque PLUS (Amersham
Biosciences, Piscataway, NJ) density gradient centrifugation
of peripheral venous blood [18]. The peripheral blood
mononuclear cells were separated into CD4+ and CD8+
T-cell populations by magnetic-activated cell separation
(Miltenyi Biotec, Bergisch Gladbach, Germany).
Co-culturing T cells with neural stem cells
To determine NSC-dependent apoptosis, CD4+ or CD8+ T
cells were cultured with HB1.F3 at a density of 5 × 104:5 ×
103, 5 × 104:1 × 104, 5 × 104:2.5 × 104, 5 × 104:5 × 104, and5 × 104:1 × 105 cells/well on 96-well plates in well media.
Adherent NSCs and nonadherent T cells were separately
harvested at the indicated times and washed in 1× PBS.
Analysis of T-cell apoptosis
Apoptotic cell death was assessed using Annexin V staining
coupled with propidium iodide (BD PharMingen,
San Diego, CA, USA). T cells were cultured with HB1.F3 at
a various densities or times. T cells were washed twice with
1× PBS. Then 2 × 105 to 5 × 105 T cells were added to a 12
mm test tube and washed twice in 1 ml of 1× binding
buffer. Cells were mixed gently with 5 μl Annexin
V–fluorescein isothiocyanate and incubated at 4°C in the
dark for 5 minutes. After washing with binding buffer, 10 μl
of the 20 μg/ml propidium iodide solution (end
concentration 1 μg/ml) and 190 μl binding buffer were
added to the cells. Cells were immediately analyzed by
fluorescence-activated cell sorting (FACS).
Flow cytometry
Adherent NSCs were trypsinized and resuspended in
staining buffer (0.1% BSA in PBS) to reach a final con-
centration of 5 × 105 to 1 × 106 cells/ml. The cells were
incubated for 20 minutes on ice with the following anti-
bodies: anti-CD27 (O323), anti-CD70 (Ki-24), anti-Fas
(APO-1), anti-FasL (NOK-1), anti-PD-1 (J105), anti-PD-
L1 (MIH1), anti-TR-1 (DJR1), anti-TR-2 (DJR2-4), and
anti-TRAIL (RIK-2). After incubation, the cells were
washed twice with staining buffer and resuspended. The
stained cells were analyzed by FACS.
Semiquantitative RT-PCR
Total RNA was prepared from CD4+ T cells using the RNA
isolation kit (QIAGEN Inc, Valencia, CA, USA). Two
micrograms of RNA were reverse-transcribed. The reaction
mixture consisted of 20 mM Tris–HCl (pH 8.4), 50 mM
KCl, 5 mM MgCl2, 10 mM dithiothreitol, 40 U of
RNaseOUT™, 1 mM dNTP, 2.5 μM of oligo(dT)20, 200 U
of SuperScript™ III reverse transcriptase (Invitrogen,
Carlsbad, CA, USA) and the remaining volume was
diethylpyrocarbonate-treated water for a total volume of 20
μl. The mixture was incubated at 50°C for 1 hour, and at
85°C for 5 minutes. For semiquantitative PCR, the reaction
mixture consisted of 10 mM Tris–HCl, 50 mM KCl, 0.1%
Triton X-100, 2 mM MgCl2, 0.4 mM dNTP, 0.2 pmol sense
and antisense primer, 2.5 U Taq DNA polymerase and 3 μg
cDNA. Primer sequences are provided in Additional file 1.
HLA-A, HLA-B and HLA-DR allele on HB1.F3 cells
We examined HLA-A, HLA-B, and HLA-DR alleles on
HB1.F3 cells using the PCR sequence-specific oligo-
nucleotide method (Dynal RELI™ HLA typing kit, Dynal
Biotech, Wirral, U.K.) [19]. The results are provided in
Additional file 2.
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CD4+ T cells were incubated with HB1.F3 for 24 hours
with a series of concentrations of neutralizing Fas ligand
mAb (NOK-2): 0, 0.01, 0.1, 0.5, and 1 μg/ml.Treatment of actinomycin D and cycloheximide
We treated a transcription inhibitor, actinomycin D
(1 μg/ml; Sigma-Aldrich, St. Louis, MO, USA), on CD4+ T
cells for 1 hour before co-culture with HB1.F3. The cells
were co-cultured for 0 to 18 hours, and death ligand on
CD4+ T cells was assessed at the transcriptional level
by RT-PCR. We treated a translation inhibitor, CHX
(10 μg/ml, Sigma-Aldrich, St. Louis, MO, USA) on T cells
for 12 hours before co-culture with HB1.F3. The cells co-
cultured for 12 hours, and intracellular Fas ligand expres-
sion on CD4+ or CD8+ T cells and HB1.F3 was assessed
by FACS.Treatment of anti-human CD27 or CD70 mAbs
CD4+ T cells were incubated with HB1.F3 for 12 hours
with a series of concentrations of anti-CD27 (LG.7F9)
or anti-CD70 mAb (BU69): 0, 0.01, 0.1, 0.5, and
1 μg/ml.Figure 1 Human neural stem cells (HB1.F3) induce T-cell apoptosis. (A
was characteristic of apoptotic cells: blebbing and shrinkage of cytoplasm
24 hrs (■, AV+/PI- and AV+/PI+ cells), however the total dead cells of T cell
and AV -/PI+ cells). (C) The degree of CD4+ T-cell apoptosis occurred in an
apoptosis by pNSCs or HB1.F3, the apoptosis levels of CD4+ T cells by HEK-
mesenchymal stem cells did not significantly differ from each other. MSC, mCombinatory treatment of anti-CD27, anti-PD-L1, or
anti-CD40 mAb
CD4+ T cells were incubated with HB1.F3 for 24 hours
with 0.5 μg/ml of anti-CD27 (LG.7F9), anti-PD-L1
(MIH-1), or anti-CD40 mAb (5C3).Statistical analysis
All results are expressed as the mean ± standard devi-
ation. The statistical significance of differences between
group means was determined using Student’s t test.Results
Human neural stem cells induce CD4+ T-cell apoptosis
To assess the extent of allogeneic response against
NSCs, the in vitro response of human T cells was mea-
sured towards the fetal NSC line HB1.F3 [20]. Surpris-
ingly, the majority of human T cells displayed morphology
of apoptotic cells within 24 hours upon incubation with
HB1.F3 (Figure 1A). Apoptosis of T cells commenced
within 6 to 12 hours and reached the maximum at 24
hours after co-culturing with HB1.F3 (Figure 1B). The
induction of cell death was prominent for CD4+ T
cells, affecting ~30 to 40% above the background, but
was negligible for CD8+ T cells (Figure 1B). The extent of) The morphology of CD4+ T cells after the co-culture with HB1.F3
(scale bar: 20 μm). (B) CD4+ T cells showed maximal apoptosis at
s increased by time dependent manner ( , total of AV+/PI-, AV+/PI+,
HB1.F3 density-dependent manner. (D) Contrary to CD4+ T-cell
293, Detroit 551, and human umbilical cord blood-derived
esenchymal stem cell; NSC, neural stem cell.
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to T cells, while the extent of CD8+ T-cell apoptosis did
not rise with elevated HB1.F3 ratio (Figure 1C). In ad-
dition to HB1.F3, primary NSCs induced CD4+ T-cell
apoptosis. NSCs appear unique in their ability to induce
apoptosis of CD4+ T cells, because other types of cells, in-
cluding fibroblasts, epithelial cells, and even stem cells of
another lineage (mesenchymal stem cells), did not induce
apoptosis of CD4+ T cells (Figure 1D).Fas–Fas ligand interaction is involved in neural stem
cell-induced T-cell apoptosis
To determine the mechanism of T-cell apoptosis med-
iated by NSCs, we analyzed for expression of death-
inducing molecules Fas, FasL, PD-1, PD-L1, TRAIL
receptor-1, TRAIL receptor-2, and TRAIL on HB1.F3, as
these molecules were previously reported to be present
on stem cells [21-24]. HB1.F3 cells expressed high levels
of Fas and TRAIL receptor-2 on cell surface, but not
FasL, TRAIL, and PD-1 (Figure 2A). Since human PBL
do not express FasL [25], T cells presumably upregulated
FasL in order to be susceptible to Fas-mediated cell
death by NSCs. To confirm this notion, FasL expression
on T cells was analyzed after co-culture with HB1.F3
cells. FasL expression on the cell surface was slightly
upregulated on the majority of CD4+ T cells and a small
fraction (~7.3%) of cells expressed high levels of FasL
(109.96 ± 11.52) (Figure 2B,C). The peak of FasL
upregulation was at 12 hours post incubation with HB1.
F3. In contrast to CD4+ T cells, FasL upregulation was
minimal on CD8+ T cells (Figure 2C). After blocking of
Fas-FasL interaction with an anti-FasL mAb (NOK-2)
inhibited NSCs-induced CD4+ T cell apoptosis in a
dose-dependent manner (Figure 2D).Neural stem cells induce Fas ligand upregulation on
T cells
Induction of FasL was evident also at the mRNA level
in CD4+ T cells within 12 hours after interaction with
HB1.F3 cells (Figure 3A). FasL mRNA upregulation was
blocked by actinomycin D, indicating new synthesis of
FasL (Figure 3A). Figure 3B and C shows the intracellular
FasL expression levels on co-cultured CD4+ T cells and
CD8+ T cells, and HB1.F3 without cycloheximide and
with cycloheximide. Intracellular FasL upregulation was
higher on CD4+ T cells than CD8+ T cells. Upregulation
of FasL on CD4+ T cells was blocked by cycloheximide,
but not CD8+ T cells. Intracellular FasL expression on
CD4+ T cells and co-cultured HB1.F3 were reduced about
50% (46.91 vs. 22.43, 13.14 vs. 6.66; Figure 3B). On the
other hand, intracellular FasL expression on CD8+ T cells
and co-cultured HB1.F3 was increased slightly (3.04 vs.
17.82, 1.38 vs. 5.16; Figure 3C). Cycloheximide is assumedto affect the Fas-induced apoptosis on CD8+ T cells and
HB1.F3.
CD70–CD27 interaction is involved in neural stem cell-
induced CD4+ T-cell death
To determine the molecular interactions responsible for
induction of FasL on CD4+ T cells, we assessed expres-
sion of several co-stimulatory molecules on HB1.F3 and
T cells by RT-PCR. HB1.F3 constitutively expressed
CD70 mRNA, but not other co-stimulatory molecules,
including 4-1BBL, CD80, CD86, ICOSL, and OX40L
(Figure 4A). The expression pattern of these co-
stimulatory molecules on NSCs was confirmed by FACS
analysis, which showed that the majority of both HB1.F3
and primary NSCs expressed CD70, but not other mo-
lecules (Figure 4B and data not shown). As reported pre-
viously [26], freshly purified human CD4+ and CD8+
T cells were found to express mRNA for CD27, the re-
ceptor for CD70, and other co-stimulatory molecules,
including CD28, HVEM and ICOS (Figure 4A). In ad-
dition, as reported previously [27], CD27 expression was
found on nearly on all human CD4+ T cells, but only ≈
50% on CD8+ T cells (Figure 4B). The presence of CD70
on NSCs and CD27 on T cells led us to consider the
possibility that CD70–CD27 interaction could play an
important role in NSC-induced apoptosis of the T cells.
To this end, the effect of anti-CD27 or anti-CD70 bloc-
king antibodies was evaluated. The presence of either
blocking antibody inhibited NSC-mediated death of
CD4+ T cells in a dose-dependent manner, but only
at ~50% of the level, with anti-CD70 blocking antibodies
mediating a slightly stronger inhibition (Figure 4C). A
synergistic effect of the two blocking antibodies was ob-
served as the presence of both blocking antibodies did
lead to an enhanced, but incomplete, inhibition of apop-
tosis (Figure 4C). Otherwise, we found the expression of
PD-L1 on HB1.F3 (as in Figure 2A). In a related study,
PD-L1-induced effector T-cell apoptosis was known as a
mechanism of immune privilege of corneal allografts
[28]. The CD40 system also regulates apoptosis, posi-
tively or negatively, depending on the target cells. We
therefore confirmed whether PD-L1 and CD40 were in-
volved in T-cell apoptosis by HB1.F3. Figure 4D shows
the inhibitory effects by the addition of anti-CD40 or
anti-PD-L1 mAb with anti-CD27 mAb. Also, after treat-
ment with anti-CD27 mAbs, the number of FasL-
positive CD4+ T cells was markedly reduced to the base-
line level (Figure 4E).
Discussion
Immune escape induced by stem cells is partly due to
reduced expression of several cell surface molecules of
immune activation on stem cell surfaces. For example,
reduced alloreactivity caused by lack of MHC II and
Figure 2 Effect of Fas ligand expression on HB1.F3-induced T-cell apoptosis. (A) Fas, PD-L1, and TR-2 (TRAIL receptor-2) were expressed on
HB1.F3 cells. (B) CD4+ T cells, CD8+ T cells, and HB1.F3 cells constitutively did not express Fas ligand (FasL). FasL expression on CD4+ T cells
co-cultured with HB1.F3 was induced at 12 hours, but FasL expression on CD8+ T cells was much less dramatic. The FasL level of CD4+ T cells
was higher than CD8+ T cells in a small population. (C) FasL (median fluorescence intensity) on CD8+ T cells did not significantly change (dark
shading) during the co-culture period, whereas marked FasL upregulation on CD4+ T cells was detected (no shading). (D) The inhibition of CD4+
T cells apoptosis showed anti-FasL mAbs dose-dependent manner.
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[29]. Others have reported that stem cells induced T-cell
apoptosis by Fas–FasL interaction, which had been ob-
served to be one of the immune escape mechanisms on
T cells [5,30].
CD4+ T-cell apoptosis seemed to continuously occur
even 24 hours after the co-culture, because the number ofpropidium iodide-positive cells continuously increased even
after the number of Annexin V-positive cells reached its
peak at 24 hours. However, it has not been clearly demon-
strated whether this reaction was caused by direct inter-
action between the FasL expressed on the surface of NSCs
and Fas on CD4+ T cells. Similar to other researchers'
observations of human ESCs in various stages of
Figure 3 The effect of Actinomycin D and cycloheximide on death ligand expression levels on CD4+ T cells and HB1.F3. (A) Actinomycin
D (Act D) abolished induction of Fas ligand (FasL) transcription on CD4+ T cells at 12 hours, but TRAIL has no differences in the co-culture period.
(B), (C) Intracellular FasL expression levels on co-cultured CD4+ T cells and CD8+ T cells, and HB1.F3 without cycloheximide (CHX−) and with
cycloheximide (CHX+). Intracellular FasL expression on CD4+ T cells and co-cultured HB1.F3 were reduced about 50% (46.91 vs. 22.43, 13.14 vs.
6.66 (B)). On the other hand, intracellular FasL of CD8+ T cells and co-cultured HB1.F3 were increased slightly (3.04 vs. 17.82, 1.38 vs. 5.16 (C)).
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or surface protein by FACS in NSCs. FasL expression on
HB1.F3 was examined using FACS analysis and immuno-
cytochemistry. Both results showed an absence of FasL on
HB1.F3, which was similar to the previous results of a study
performed with ESCs [29]. Direct Fas–FasL interactions
between NSC and CD4+ T cells are therefore less likely to
occur (see Additional file 3). NSCs must therefore have
provoked Fas–FasL-mediated CD4+ T-cell apoptosis
through an indirect pathway.
In addition, transplant rejection occurs through recog-
nition of foreign antigens presented by MHC molecules
expressed on antigen-presenting cells, a process that can
be mimicked by triggering T cells with CD3-specific
mAb [31]. We used anti-CD3 (OKT3) and anti-CD28
(CD28.2) mAbs, and recombinant mouse CD27L
(Minneapolis, MN, USA) to stimulate T cells in a man-
ner that partially mimics stimulation by antigen-
presenting cells. We then checked FasL expression and
apoptosis of CD4+ T cells. Our previous data showed an
increase of FasL-positive cells and apoptotic CD4+ Tcells by antigen presentation by T-cell receptor and co-
stimulatory signals. However, the median fluorescence
intensity of FasL and the apoptosis level varied by blood
donor, incubation time, and the combinations of anti-
bodies and recombinant protein (see Additional file 4).
In this paper, we demonstrated that CD70–CD27
interaction was involved in NSCs-induced CD4+ T cell
apoptosis. Originally, CD27 is a cell surface glycoprotein
belonging to the TNF receptor superfamily, which can
provide stimulatory signals for both cell growth and
apoptosis. CD70–CD27 interactions between most im-
mune cells produce T cell expansion and the develop-
ment of effector cytotoxic or memory T cells [32]. On
the other hand, it has been reported that CD27 can bind
apoptosis-inducing factor (Siva 1), an intracellular medi-
ator of apoptosis [33,34], but the role of this interaction
for the function of CD27 is yet to be resolved, because
ligation of CD27 generally does not limit but rather con-
tributes to the expansion of activated lymphocytes [35].
CD70 expressed on malignant cells showed novel
function in immune escape [36]. Human brain tumor
Figure 4 CD70-CD27 interaction was involved in HB1.F3-induced T cell apoptosis. (A) While constitutive expression of CD70 mRNA was
detected on HB1.F3, other co-signaling molecule mRNA was not detected. T cells constitutively expressed CD27 as well as several the other
co-signaling molecules such as CD28, CTLA4, HVEM, and ICOS. (B) CD70 expression on HB1.F3 and CD27 on T cells was also confirmed by
fluorescence-activated cell sorting (FACS). CD27 expression level on CD4+ T cells were above 90%, but CD8+ T cells were about 50%. (C) Addition
of anti-CD27 and CD70 mAbs resulted in a dose-dependent inhibition of the CD4+ T-cell apoptosis but did not inhibit the apoptosis completely
(■, CD4+ T cells only; ○, CD4+ T cells co-cultured w/ HB1.F3 + isotype control mAbs); ●, CD4+ T cells co-cultured w/ HB1.F3 + anti- CD27 or
anti-CD70 mAbs). (D) To assess the impact of anti-CD40 and PD-L1 mAbs on the CD4+ T-cell apoptosis, we measured the CD4+ T-cell
apoptosis ratio after anti-CD27, anti-CD40 or anti-PD-L1 mAbs treatment. This showed an inhibitory effect of the CD4+ T-cell apoptosis
compared with the media control group (□, CD4+ T cells only; ■, CD4+ T cells w/ HB1.F3). (E) FasL expression level on CD4+ T cells reduced
about 50% by addition of anti-CD27 mAb.
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multiforme, express CD70 [37], and this CD70 – but
not TNFα or FasL – initiated T-cell death through
the receptor-dependent pathway [38]. However, the
exact mechanism of this process is not yet fully
understood.
Levels of inhibition by both antibodies were otherwise
incomplete, implicating the existence of other causes for
apoptosis in addition to CD70–CD27 interaction. In
CD70-mediated T-cell apoptosis, the role of Siva, a pro-
apoptotic molecule, was identified, as well as soluble me-
diators such as transforming growth factor beta [32,39].
We evaluated the expression of Siva protein using
western blotting. Siva was increased at 48 hours in CD4+
T cells and the NSC co-culture system. We therefore think
that, at least in our system, apoptosis was mainly
induced by the FasL upregulation by CD27–CD70
ligation between NSCs and CD4+ T cells in the early
phase (see Additional file 5).
We then examined cytokine profiles from the super-
natant at various co-culture times (1, 3, 6, 12, 18, and 24
hours). Several cytokines (such as IL-1β, TNFα, IL-4,
IL-10, IFNγ, IL-5, and IL-13) were shown to be negative in
the co-culture periods. Moreover, IL-6 increased in a
time-dependent manner. However, the IL-6 level is similar
in the NSC-only culture group. In addition, the super-
natant of the CD4+ T-cell-only culture group was shown
to be negative for IL-6. Therefore, IL-6 might require
NSC self-renewal and progenitor cell division and differ-
entiation [40-42]. As in ESCs, lack of co-stimulation [9,43]
or participation of soluble mediators could play a role in
T-cell immune escape. However, activation-induced cell
death was less likely to play a role [44] since CD4+ T-cell
apoptosis in our experiments reached its peak in 24 hours.
Finally, we have demonstrated that FasL expression on
CD4+ T cells was significantly increased as a consequence
of CD70–CD27 ligation. Antibody blocking experiments
also confirmed that FasL expression on CD4+ T cells was
CD70–CD27 dependent. NSCs therefore probably induce
CD4+ T-cell apoptosis in two stages: CD70–CD27 ligation
between NSCs and CD4+ T cells, which induces FasL
expression on some CD4+ T cells, followed by Fas–FasL-
mediated CD4+ T-cell apoptosis.
Conclusion
We demonstrated CD70–CD27 ligation to be an initiating
step for NSC-induced CD4+ T-cell apoptosis. NSCs proba-
bly induce CD4+ T-cell apoptosis in two stages: CD70–
CD27 ligation between NSCs and CD4+ T cells, which
induces FasL expression on some CD4+ T cells, followed
by Fas–FasL-mediated CD4+ T-cell apoptosis. Therefore, if
it is possible to maintain persistent expression of CD70
using a gene delivery technique, this will be an exciting op-
tion to maintain immune escape in NSC transplantation.Additional files
Additional file 1: a table presenting primer sequences for the
RT-PCR.
Additional file 2: a table presenting phenotype and gene
frequencies of HLA-A, HLA-B, HLA-DR loci on HB1.F3 cells defined
by DNA typing method.
Additional file 3: a figure showing FasL expression on CD4+ T cells
(left) and apoptosis of CD4+ T cells (right) increased by anti-CD3
(OKT-3, 1 μg/ml; eBioscience, San Diego, CA, USA) and anti-CD28
(CD28.2, 1 μg/ml; BD Pharmingen, San Diego, CA, USA) agonistic
antibodies, and recombinant CD27L (1 μg/ml; R&D Systems)
treatment (no shading, CD4+ T + anti-CD3; solid shading, CD4+ T +
msCD27L; vertical shading, CD4+ T + anti-CD28; diagonal shading,
CD4+ T + anti-CD3 +msCD27L; diagonal crosshatch, CD4+ T + anti-
CD3 +msCD27L + anti-CD28). The experiment shown is representative
of three independent experiments with three different blood donors.
Additional file 4: a figure showing expression of FasL on co-cultured
NSCs with allogeneic T cells was examined using FACS analysis
(NOK-1) and immunocytochemistry (G247-4). (A) NSCs constitutively
did not express FasL. We were able to check the expressions of FasL after
IL-1β treatment on NSCs (positive control). (B) FasL expression on
co-cultured NSCs with allogeneic T cells was not detected.
Additional file 5: a figure showing expression of Siva on
co-cultured T cells with NSCs. Co-cultured CD4+ T-cell lysate was
tested with anti-Siva antibodies (clone C-20; Santa Cruz, CA, USA) by
western blotting. α-tubulin was used as a loading control.
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